Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468153 | 0.88 | DHFR (0.51) | HSD17B2DHFR | |
| SCHEMBL10784527 | 0.86 | PTGS1 (0.49) | FFAR1 | |
| SCHEMBL22122696 | 0.83 | KMT2A (0.47) | L3MBTL1DHFR | |
| SCHEMBL2685285 | 0.83 | APP (0.49) | DHFR | |
| SCHEMBL2683955 | 0.83 | KMT2A (0.47) | L3MBTL1DHFR | |
| SCHEMBL23572596 | 0.83 | APP (0.49) | DHFR | |
| SCHEMBL13859211 | 0.81 | DHFR (0.45) | L3MBTL1DHFR | |
| SCHEMBL2803495 | 0.80 | AOC3 (0.47) | AOC3L3MBTL1CASRMTNR1AMTNR1B | |
| SCHEMBL2683823 | 0.80 | ACP3 (0.45) | HSD17B2FFAR1PKMGRM5PTGES | |
| SCHEMBL2519799 | 0.78 | TSHR (0.52) | FFAR1PKMGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461501-A | Green method for high-selectivity synthesis of chalcone compounds | 温州大学 | 2021-10-01 | — | — | CN | disclosed |
| US-7763734-B2 | Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis | GEORGETOWN UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763734-B2 | Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis | GEORGETOWN UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| EP-0755527-A4 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES INC (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0755527-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | ADH5, ADH1C, ADH1A | AOC3 62/4885L3MBTL1 3151/4885HSD17B2 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.